Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches
- 531 Downloads
Desomorphine is an opioid misused as “crocodile”, a cheaper alternative to heroin. It is a crude synthesis product homemade from codeine with toxic byproducts. The aim of the present work was to investigate the metabolic fate of desomorphine in vivo using rat urine and in vitro using pooled human liver microsomes and cytosol as well as human liver cell lines (HepG2 and HepaRG) by Orbitrap-based liquid chromatography-high resolution-tandem mass spectrometry or hydrophilic interaction liquid chromatography. According to the identified metabolites, the following metabolic steps could be proposed: N-demethylation, hydroxylation at various positions, N-oxidation, glucuronidation, and sulfation. The cytochrome P450 (CYP) initial activity screening revealed CYP3A4 to be the only CYP involved in all phase I steps. UDP-glucuronyltransferase (UGT) initial activity screening showed that UGT1A1, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17 formed desomorphine glucuronide. Among the tested in vitro models, HepaRG cells were identified to be the most suitable tool for prediction of human hepatic phase I and II metabolism of drugs of abuse. Finally, desomorphine (crocodile) consumption should be detectable by all standard urine screening approaches mainly via the parent compound and/or its glucuronide assuming similar kinetics in rats and humans.
KeywordsDesomorphine Crocodile LC-HR-MS/MS Metabolism Human liver preparation Hepatocyte cell cultures
The authors thank Achim T. Caspar, Julia Dinger, Andreas G. Helfer, Julian A. Michely, Carsten Schröder, Gabriele Ulrich, Lea Wagmann, and Armin A. Weber for support and/or helpful discussion. The research leading to these results partly received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 267038 and Cosmetics Europe within the framework of the NOTOX project of the SEURAT-1 (safety evaluation ultimately replacing animal testing) initiative.
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest and that they followed the national guidelines for animal ethical care.
- 4.United Nations Office on Drugs and Crime (UNODC) (2015) World Drug Report 2015. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf.
- 10.Maurer HH, Pfleger K, Weber AA. Mass spectral library of drugs, poisons, pesticides, pollutants and their metabolites. Weinheim: Wiley-VCH; 2016.Google Scholar
- 14.Schwaninger AE, Meyer MR, Zapp J, Maurer HH. Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicol Lett. 2011;202:120–8.CrossRefGoogle Scholar
- 18.Wink CSD, Meyer GMJ, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH. Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-high resolution (HR)-MS/MS. Drug Test Anal. 2014;6:1038–48.CrossRefGoogle Scholar
- 19.Caspar AT, Helfer AG, Michely JA, Auwaerter V, Brandt SD, Meyer MR, et al. Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS. Anal Bioanal Chem. 2015;407:6697–719.CrossRefGoogle Scholar
- 21.Maurer HH, Wissenbach DK, Weber AA. Maurer/Wissenbach/Weber MWW LC-MSn library of drugs, poisons, and their metabolites. Weinheim (Germany): Wiley-VCH; 2014.Google Scholar
- 23.Fenselau C. Applications of mass spectrometry. In: Kuwana T, editor. Physical methods in modern chemical analysis. New York: Academic Press; 1978. p. 110–1.Google Scholar
- 24.Mardal M, Gracia-Lor E, Leibnitz S, Castiglioni S, Meyer MR. Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MS. Drug Test Anal. 2016. doi: 10.1002/dta.1938.Google Scholar
- 32.Wink CSD, Meyer GMJ, Zapp J, Maurer HH. Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS. Anal Bioanal Chem. 2015;407:1545–57.CrossRefGoogle Scholar
- 33.Yamazaki H. Fifty years of cytochrome P450 research. Tokyo: Springer; 2014. p. 293–306.Google Scholar
- 36.Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012;28:69–87.CrossRefGoogle Scholar
- 41.Eddy NB, Halbach H, Braenden OJ. Synthetic substances with morphine-like effect: clinical experience; potency, side-effects, addiction liability. Bull World Health Organ. 1957;17:569–863.Google Scholar